Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Trial of epicutaneous immunotherapy in eosinophilic esophagitis

Key clinical point: For children with milk-induced eosinophilic esophagitis, 9 months of epicutaneous immunotherapy with Viaskin Milk did not reduce maximum esophageal eosinophil counts, compared with placebo.

Major finding: In the intention-to-treat analysis, average maximum eosinophil counts were 50.1 per high-power field in the Viaskin Milk group versus 48.2 in the placebo group.Study details: Double-blind pilot study of 20 children with milk-induced eosinophilic esophagitis.

Disclosures: The study was funded by DBV Technologies and by the Children’s Hospital of Philadelphia Eosinophilic Esophagitis Family Fund. Dr. Spergel disclosed consulting agreements, grants funding, and stock equity with DBV Technologies. Three coinvestigators also disclosed ties to DBV. The remaining five coinvestigators reported having no conflicts of interest.

Citation:

Spergel JM et al. Clin Gastroenterol Hepatol. 2019 May 14. doi: 10.1016/j.cgh.2019.05.014.